Structure of compound 46

oral sel. PDE2A phosphodiesterase inhibitor

for cognition, target engagement in brain

from HTS, SBDD, and FEP claculations

J. Med. Chem., Oct. 26, 2020

Janssen Pharmaceutica NV, Beerse, BE

“compound 46” (Janssen oral selective brain-penetrant PDE2A phosphodiesterase inhibitor)


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.